ZILACTIN
Zila Pharmaceuticals, Inc.
| Research |
OneLook
Acronym Finder
|
| Serial Number | 73480210 |
| Registration Number | 1347149 |
| Mark Drawing Code | 1000: Typeset: Word(s)/letter(s)/number(s) |
| Attorney Name | E. VICTOR INDIANO |
| Attorney Docket Number | 7419-0108 |
| Law Office Assigned | 570 |
Timeline
| 1984-03-15 | Date of First Use |
| 1984-05-14 | Application Filed |
| 1985-04-30 | Published for Opposition |
| 1985-07-09 | Trademark Registered |
| 2015-05-27 | Location: GENERIC WEB UPDATE |
| 2015-05-27 | Status: Live/Registered |
| 2015-07-09 | Renewal Date |
| 2018-07-07 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Zila Pharmaceuticals, Inc. |
| Address | 777 E. Thomas, #120 Phoenix NV 85014 |
| Legal Entity Type | Corporation |
| Legal Entity State | IN |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 018 |
| Type Code | Type |
|---|---|
| GS0051 | Composition for the Treatment of Herpes Infections |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| ASSIGNED TO EXAMINER | 1984-09-10 | 1 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 1984-09-18 | 2 CNSA O:Outgoing Correspondence |
| NOTICE OF PUBLICATION | 1985-04-04 | 3 NPUB O:Outgoing Correspondence |
| PUBLISHED FOR OPPOSITION | 1985-04-30 | 4 PUBO A:Allowance for Publication |
| REGISTERED-PRINCIPAL REGISTER | 1985-07-09 | 5 R.PR A:Allowance for Publication |
| REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | 1990-11-19 | 6 815F I:Incoming Correspondence |
| REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | 1991-02-11 | 7 C15A O:Outgoing Correspondence |
| PAPER RECEIVED | 2002-03-18 | 8 MAIL I:Incoming Correspondence |
| PAPER RECEIVED | 2005-11-30 | 9 MAIL I:Incoming Correspondence |
| REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED | 2005-11-30 | 10 89AF I:Incoming Correspondence |
| ASSIGNED TO PARALEGAL | 2005-12-20 | 11 PLGL A:Allowance for Publication |
| REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | 2006-01-07 | 12 89AG O:Outgoing Correspondence |
| REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | 2006-01-07 | 13 RNL1 Q: |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2006-12-04 | 14 TCCA I:Incoming Correspondence |
| CASE FILE IN TICRS | 2008-06-16 | 15 CFIT O:Outgoing Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2011-12-05 | 16 TCCA I:Incoming Correspondence |
| TEAS SECTION 8 & 9 RECEIVED | 2015-05-21 | 17 E89R I:Incoming Correspondence |
| REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | 2015-05-27 | 18 89AG O:Outgoing Correspondence |
| REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) | 2015-05-27 | 19 RNL2 Q: |
| NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | 2015-05-27 | 20 NA89 E:E-Mail |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2015-10-14 | 21 TCCA I:Incoming Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ZILACTIN 78332516 2905201 Live/Registered |
BLAIREX LABORATORIES, INC. 2003-11-24 |
 ZILACTIN 73480210 1347149 Live/Registered |
Zila Pharmaceuticals, Inc. 1984-05-14 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 